Thomas P Blaisdell

This inventor holds 17 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Enanta Pharmaceuticals, Inc., Cedilla Therapeutics, Inc.. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas P Blaisdell. Retrieved from https://idiyas.com/inventor/thomas-p-blaisdell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 13)

% Patents Active = 82.4

CIPO Patents = 1 (Patent Applications = 11)

EPO Patents = 4 (Patent Applications = 16)

Average Co-Inventor Count = 6.2

ph-index = 4

Forward Citations = 112(Granted Patents)

Location History:

Brighton, MA (US) (2018 - 2021)
Watertown, MA (US) (2022 - 2024)

Company Filing History:

16 out of 299

Enanta Pharmaceuticals, Inc.

patents

1 out of 3

Cedilla Therapeutics, Inc.

patents

Years Active: 2018-2025

Loading Chart...

Areas of Expertise:

Benzodiazepine Derivatives

RSV Inhibitors

Heterocyclic Compounds

Combination Pharmaceutical Agents

CDK2 Inhibitors

Aryldiazepine Derivatives

Azepin-2-One Derivatives

Heteroaryldiazepine Derivatives

Pharmaceutical Agents

Drug Development

Chemical Processes

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297209 - Benzodiazepine derivatives as RSV inhibitors (2025-05-13),

2. 12268694 - Combination pharmaceutical agents as RSV inhibitors (2025-04-08),

3. 12065445 - CDK2 inhibitors and methods of using the same (2024-08-20),

4. 11952389 - Benzodiazepine derivatives as RSV inhibitors (2024-04-09),

5. 11390631 - Benzodiazepine derivatives as RSV inhibitors (2022-07-19),

6. 11091501 - Heterocyclic compounds as RSV inhibitors (2021-08-17),

7. 10906895 - Processes for the preparation of benzodiazepine derivatives (2021-02-02),

8. 10881666 - Combination pharmaceutical agents as RSV inhibitors (2021-01-05),

9. 10865215 - Benzodiazepine derivatives as RSV inhibitors (2020-12-15),

10. 10851115 - Heterocyclic compounds as RSV inhibitors (2020-12-01),

11. 10759816 - Heterocyclic compounds as RSV inhibitors (2020-09-01),

12. 10752598 - Aryldiazepine derivatives as RSV inhibitors (2020-08-25),

13. 10647711 - Azepin-2-one derivatives as RSV inhibitors (2020-05-12),

14. 10570153 - Benzodiazepine derivatives as RSV inhibitors (2020-02-25),

15. 10398706 - Heteroaryldiazepine derivatives as RSV inhibitors (2019-09-03),

Title: Innovator Thomas P Blaisdell: Pioneering Advances in RSV Treatment

Introduction: Thomas P Blaisdell, based in Brighton, MA, is a prolific inventor recognized for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 17 patents, he has carved a niche in developing innovative therapeutic compounds aimed at inhibiting respiratory viruses.

Latest Patents: Among his latest inventions, Blaisdell has developed benzodiazepine derivatives that serve as inhibitors of Respiratory Syncytial Virus (RSV). This invention discloses specific compounds that include pharmaceutically acceptable salts, esters, or prodrugs, which are designed to inhibit RSV effectively. Additionally, his patent on combination pharmaceutical agents offers a dual approach to treating RSV infections by incorporating a secondary anti-respiratory syncytial virus agent alongside his innovative compounds.

Career Highlights: Throughout his career, Blaisdell has collaborated with leading companies in the pharmaceutical sector, including Enanta Pharmaceuticals, Inc. and Cedilla Therapeutics, Inc. His work has played a crucial role in advancing treatments for viral infections, particularly those affecting the respiratory system.

Collaborations: One of the hallmarks of Blaisdell’s innovative journey has been his collaborations with other esteemed professionals in the field. Notable colleagues, such as Brian Christopher Shook and In Jong Kim, have joined him in pioneering research that leads to the development of cutting-edge pharmaceutical solutions.

Conclusion: Thomas P Blaisdell stands as a significant figure in the realm of pharmaceutical innovations, particularly in the fight against RSV. His dedication and inventive spirit exemplify the essence of progress in medical science, making strides that could transform treatment protocols for viral infections. His ongoing work continues to inspire future innovations in healthcare.

Profile summary based on public USPTO records.